AD)	

Award Number: DAMD17-01-1-0283

TITLE: Molecular Epidemiology of Breast Cancer in Korean Women

PRINCIPAL INVESTIGATOR: Edward W. Gabrielson, M.D.

CONTRACTING ORGANIZATION: Johns Hopkins University

Baltimore, MD 21205

REPORT DATE: August 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT

Form Approved OMB No. 074-0188

DOCUMENTATION PAGE

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

### A. HTTLE AND SUBTITLE ### Molecular Epidemiology of Breast Cancer in Korean Women ### DAMD17-01-1-0283 ### DAMD17-01-1-0283 ### DAMD17-01-1-0283 ### DAMD17-01-1-0283 ### DAMD17-01-1-0283 ### DAMD17-01-1-0283 ### B. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) ### Baltimore, MD 21205 ### Baltimore, MD 21205 ### Baltimore, MD 21205 ### BACKOY NAME(S) AND ADDRESS(ES) ### U.S. Army Medical Research and Material Command Fort Detrick, Maryland 21702-5012 ### DETAILS OF THE PROOF OF THE PAGE TO BE ADDRESS(ES) ### DAMD17-01-1-0283 ### B. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) ### B. PERFORMING ORGANIZATION ORGANIZATION NAME(S) ADDRESS(ES) ### B. PERFORMING ORGANIZATION NAME(S) ADDRESS(ES) ### B. PERFORMING ORGANIZATION ORGAN	1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE August 2003	3. REPORT TYPE AND DATES COVERED Annual (15 Jul 2002 - 14 Jul 2003)			
6. AUTHORIS) Edward W. Gabrielson, M.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Johns Hopkins University Baltimore, MD 21205 EMail: egabriel@jhmi.edu 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) No Abstract Provided Breast Cancer 17. SECURITY CLASSIFICATION OF THIS PAGE 18. PERFORMING ORGANIZATION PREPORT NUMBER 10. SPONSORING / MONITORING AGENCY REPORT NUMBER 10. SPONSORING / MONITORING AGENCY REPORT NUMBER 12b. DISTRIBUTION CODE 15. NUMBER OF PAGES 5 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE OF REPORT 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT	4. TITLE AND SUBTITLE				5. FUNDING NUMBERS	
Edward W. Gabrielson, M.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Johns Hopkins University Baltimore, MD 21205 E-Mall: egabriel@jhmi.edu 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) No Abstract Provided Breast Cancer 17. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT	Molecular Epidemiology	DAMD17-01-1-0283				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Johns Hopkins University Baltimore, MD 21205 E-Mail: egabriel@jhmi.edu 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) No Abstract Provided 15. NUMBER OF PAGES 5 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT	6. AUTHOR(S)					
Johns Hopkins University Baltimore, MD 21205 E-Mail: egabriel@jhmi.edu 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Port Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) No Abstract Provided 15. NUMBER OF PAGES 5 16. FRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE OF ABSTRACT 20. LIMITATION OF ABSTRACT OF REPORT 21. SECURITY CLASSIFICATION OF ABSTRACT OF REPORT 22. LIMITATION OF ABSTRACT 23. ON THIS PAGE 24. SECURITY CLASSIFICATION OF ABSTRACT 25. CLIMITATION OF ABSTRACT 26. LIMITATION OF ABSTRACT 26. LIMITATION OF ABSTRACT 27. SECURITY CLASSIFICATION OF ABSTRACT 28. SECURITY CLASSIFICATION OF ABSTRACT 29. LIMITATION OF ABSTRACT 20. LIMITATI	Edward W. Gabrielson, I	M.D.				
Johns Hopkins University Baltimore, MD 21205 E-Mall: egabriel@jhmi.edu 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) No Abstract Provided 15. NUMBER OF PAGES 5 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE OF REPORT 18. SECURITY CLASSIFICATION OF ABSTRACT OF REPORT 20. LIMITATION OF ABSTRACT	7. PERFORMING ORGANIZATION N	AME(S) AND ADDRESS(ES)				
9. SPONSORING / MONITORING AGENCY NAME(s) AND ADDRESS(ES) U.S. ARMY Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) No Abstract Provided 15. NUMBER OF PAGES Breast Cancer 17. SECURITY CLASSIFICATION OF THIS PAGE OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT 10. SPONSORING / MONITORING AGENCY REPORT NUMBER 10. SPONSORING / MONITORING AGENCY REPORT NUMBER 12b. DISTRIBUTION CODE 12b. DISTRIBUTION CODE 12c. DISTRIBUTION CODE 12b. DISTRIBUTION CODE 12c. DISTR	Baltimore, MD 21205	REPORT NO	MREK			
AGENCY NAME(s) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) No Abstract Provided 15. NUMBER OF PAGES 5 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE OF ABSTRACT 20. LIMITATION of ABSTRACT 21b. DISTRIBUTION CODE 12b. DISTRIBUTION CODE 12c. DISTRIBUTION CODE 12b. DISTRIBUTION CODE 12c. DISTRIBUTION CODE		au .		10 SPONSORING / MONITORING		
### To Patrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) No Abstract Provided 15. NUMBER OF PAGES 5 Breast Cancer 17. SECURITY CLASSIFICATION OF THIS PAGE OF THIS PAGE OF ABSTRACT 20. LIMITATION OF ABSTRACT	AGENCY NAME(S) AND ADDRE					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) No Abstract Provided 15. NUMBER OF PAGES 5 Breast Cancer 17. SECURITY CLASSIFICATION OF THIS PAGE OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT						
Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) No Abstract Provided 15. NUMBER OF PAGES 5 16. PRICE CODE 17. SECURITY CLASSIFICATION OF REPORT 18. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT	11. SUPPLEMENTARY NOTES					
Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) No Abstract Provided 15. NUMBER OF PAGES 5 16. PRICE CODE 17. SECURITY CLASSIFICATION OF REPORT 18. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT						
No Abstract Provided 15. NUMBER OF PAGES 5 16. PRICE CODE			12b. DISTRIBUTION CODE			
Breast Cancer 15. NUMBER OF PAGES 5 5 16. PRICE CODE	13. ABSTRACT (Maximum 200 Wor	rds)				
Breast Cancer 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT	No Abstract Provided					
Breast Cancer 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT						
Breast Cancer 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT						
Breast Cancer 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT						
Breast Cancer 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT						
Breast Cancer 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT				•		
Breast Cancer 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT						
Breast Cancer 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT						
Breast Cancer 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT						
Breast Cancer 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT		i e e e e e e e e e e e e e e e e e e e	HIRALIA MINISTERIO DE LA CONTRACTOR DE L			
17. SECURITY CLASSIFICATION OF THIS PAGE 18. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT	Breast Cancer			<u> </u>	-	
OF REPORT OF THIS PAGE OF ABSTRACT	17. SECURITY CLASSIFICATION	18. SECURITY CLASSIFICATION	19. SECURITY CLASSIEI			
	OF REPORT	OF THIS PAGE	OF ABSTRACT			

Table of Contents

Cover1	
SF 2982	
Table of Contents3	
Introduction4	
Body4	
Key Research Accomplishments5	
Reportable Outcomes5	
Conclusions5	
References5	
Appendicesno	ne

INTRODUCTION

This project is testing the hypothesis that populations of women with significantly different demographic characteristics may not only have different incidences of breast cancers, but also different types of breast cancers. We are testing this hypothesis by examining gene expression profiles of breast cancers from two populations that differ apparently by only a single major variable: age. Specifically, we are measuring gene expression profiles by gene array technology and by immunohistochemistry in breast cancer tissues from young and elderly Korean women. Recently published studies have shown that this approach has great potential for classifying breast cancer at the molecular level. Korean breast cancers have been selected for this project because there is much less cultural and genetic diversity in the Korean population than in the North American population.

BODY

The overall progress of this project is summarized below:

Gene array analysis to date fails to show age-specific patterns of gene expression in breast cancers (work conducted as part of Task 1).

We have measured gene expression profiles in over 20 young women (less than 45 years of age) and over 20 elderly (over 65 years of age) women using cDNA arrays that represented 12,000 human genes. We have performed both unsupervised hierarchical clustering and supervised class prediction models to determine whether the age differences in the patients determines the phenotype of breast cancer. The hierarchical clustering was performed with a variety of permutations using software developed at Stanford University (1), by adjusting cutoffs for use of genes in analysis (e.g., fold differences among samples). In none of these exploratory analyses were we able to find subclasses that were unique to either elderly or young patients.

With supervised classification methods, we assigned samples to one of two classes based on age of patient and then tested individual genes for differential expression across the two groups. Two methods were employed: a simple T statistic, and the SAM (Significance Analysis of Microarrays (2)), which also gives a measure of significance for each variable. By T test, 89 genes met a p<0.01 level of significance, but 120 genes (of 12,000) are expected to meet this level of significance by chance. Therefore, we have no reasonable certainty that any genes are differentially expressed (at a level greater than expected by chance) across the two groups. Similarly, SAM failed to show significant differential gene expression across the two groups.

We have also conducted an analysis of 158 cases of Korean breast cancers represented on tissue arrays (3), using immunohistochemical techniques. In this set of cases, 68 of the cancers are from patients less than 45 years of age and only 9 are from patients over the age of 65 years. Over 20 antibodies have been tested with these arrays, and none of the antigens show agespecific expression differences that are statistically significant. A greater percentage of the cancers from young patients are ER negative (62% vs. 44% for elderly patients), but this does not reach significance, largely because of the small number of elderly patients represented on the arrays. Additional cases from elderly patients are being collected.

KEY RESEARCH ACCOMPLISHMENTS

- Initial phase of microarray studies completed
- Supervised and Unsupervised data analysis conducted
- Tissue microarray studies initiated

REPORTABLE OUTCOMES

Work using the tissue microarrays that were developed with this funding was presented as a poster and platform presentation at the DOD Era of Hope Meeting in Orlando, Florida, September 2002. Specifically, these tissue microarrays are being used to investigate role of apoptosis protein expression in predicting outcome for these patients. A manuscript describing the profile of apoptosis proteins related to outcome in breast cancer is in preparation and will be submitted this year.

CONCLUSIONS

We have found that the gene expression profiles of breast cancers in Korean women do not show significant age-related differences. Unfortunately, these results do not warrant additional testing of the hypothesis as originally proposed. This project has generated data and resources that will lead to useful information, however. In particular, we have important findings regarding the expression of apoptosis proteins and clinical outcome in Korean breast cancer patients.

REFERENCES

- 1. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95(25):14863-8.
- 2. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-5121.
- 3. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4(7):844-7.